Epigenetic protein families: a new frontier for drug discovery

By C. Arrowsmith, C. Bountra, Paul V. Fish, Kevin Lee, M. Schapira. Nature reviews. Drug discovery, 2012

1,283 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/fd3346db3efdf967ef263b7d902523d5edecb53e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Baylin
2. Peter A. Jones
3. J. Audia
4. R. Campbell
5. Hongbin Sun
6. Chao Xu
7. Shanhui Liao
8. Manel Esteller

Citations in the corpus

• YTH Domain: A Family of N6-methyladenosine (m6A) Readers (2018, background): “In the epigenetic field, the structural information of known mediators or readers of histone acetyllysine and methyllysine has been used to guide the design and development of chemical probes [69].”
• Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria (2017, background): “Given the enthusiasm surrounding the therapeutic tractability of histone binding domains by chemical inhibitors (7), it is worth noting that our results suggest that targeting this particular bromodomain-containing epigenetic reader may not be desirable, at least in subsets of CD (or CLL or MS) pati”
• Epigenetic Determinants of Cancer. (2016, background): “The clinical successes with current epigenetic drugs have led to a big increase in interest from the pharmaceutical industry in developing compounds that will target epigenetic abnormalities in cancers (Kelly et al. 2010; Dawson et al. 2011; Arrowsmith et al. 2012).”
• Histone Modifications and Cancer. (2016, background): “…tools that can be used are the recently described selective, cell-active inhibitors of EZH2, DOT1L, SMYD2, G9a/GLP1, PRMT3, JMJD3, LSD1, BET (BRD2-4), L3MBTL1, L3MBTL3, CBP/EP300, PCAF, and BAZ bromodomains (Arrowsmith et al. 2012; Muller and Brown 2012; James et al. 2013; Gallenkamp et al. 2014).”
• The world of protein acetylation. (2016, background): “So far, 17–22 ‘classical’ KATs have been identified in the human genome [14,15,167,186].”